[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354603-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354603-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","intravesical-mycobacteria-reshape-bladder-and-gut-microbiota-in-a-murine-bladder-cancer-model","Intravesical mycobacteria reshape bladder and gut microbiota in a murine bladder cancer model","","Intravesical mycobacteria influence bladder and gut ecosystems, but the effects of Mycobacterium bovis BCG instillations on these microbiota remain unclear. This study tests, for the first time, how M. bovis BCG and Mycobacterium brumae (a non-pathogenic immunomodulator) alter microbiota composition in bladder tissue and cecal stool in healthy and tumor-bearing mice. Findings show distinct site-specific shifts in taxa and diversity, highlighting complex host–tumor–immunotherapy interactions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/intravesical-mycobacteria-reshape-bladder-and-gut-microbiota-in-a-murine-bladder-cancer-model/354603/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/intravesical-mycobacteria-reshape-bladder-and-gut-microbiota-in-a-murine-bladder-cancer-model/354603.png","ImageObject",300,407,{"name":42,"@type":43},"RuangKosong","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are the main factors driving interest in bladder microbiota for bladder cancer therapy?","Question",{"text":63,"@type":64},"Bladder microbiota may affect tumor progression and responses to intravesical therapies, including BCG instillations, and could potentially serve as noninvasive predictive biomarkers for treatment outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which mycobacterial treatments were compared in the study?",{"text":68,"@type":64},"The study evaluates the impact of Mycobacterium bovis BCG instillations and Mycobacterium brumae as a non-pathogenic immunomodulator on microbiota composition.",{"name":70,"@type":61,"acceptedAnswer":71},"How did the treatments alter microbiota differently across body sites?",{"text":72,"@type":64},"Gut and bladder compartments showed distinct changes: mycobacterial instillations increased gut microbial richness but reduced Actinobacteria, while bladder communities displayed treatment-dependent shifts in dominant taxa and richness.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354603,1790867742,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","npj | bioﬁlms and microbiomes Article  \n\n| Published in partnership with Nanyang Technological University |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s41522-026-01002-x](https://doi.org/10.1038/s41522-026-01002-x) |  |  |\n| Intravesical mycobacteria reshape bladder and gut microbiota in a murine bladder cancer model\u003Cbr> Check for updates |  |  |\n| Víctor Campo-Pérez1,7,8, Sandra Guallar-Garrido1,8, Raúl Cabrera-Rubio2,8, Paula Herrero-Abadía1, Arnau Seguí-Moll1, Manuela Torres-Puente3, Pablo Cano-Jimenez3, Iñaki Comas3,4, Eduard Torrents5,6 & Esther Julián1  |  |  |\n| The bladder microbiota may inﬂuence tumor progression and responses to intravesical therapies, yet the effects of Mycobacterium bovis BCG instillations on bladder and gut microbiota remain unexplored. This study evaluates, for the ﬁrst time, the impact of M. bovis BCG and Mycobacterium brumae , a non-pathogenic immunomodulator, on microbiota composition in bladder tissue and cecal stool of healthy and tumor-bearing mice. Mycobacterial instillations increased gut microbial richness but reduced Actinobacteria. In tumor-bearing mice, Muribaculaceae and Bacteroidaceae were enriched, while M. bovis BCG reduced Muribaculaceae and increased Rikenellaceae. In the bladder, M. brumae instillations favored Staphylococcaceae in healthy mice, while Enterococcaceae dominated most groups except M. bovis BCG-treated tumor-bearing mice. Escherichia/Shigella decreased in mycobacteria-treated tumor-bearing mice, while Burkholderia was more prevalent in untreated bladders. Notably, M. brumae increased stool alpha diversity, whereas M. bovis BCG reduced bladder richness. These ﬁndings reveal that intravesical mycobacterial therapy modulates microbiota composition across body sites, underscoring the complex host-tumor-immunotherapy interplay. |  |  |\n| Bladder cancer(BC)isthetenth most common malignancyworldwide,with approximately 600,000 new cases and over 200,000 deaths reported annually1. At diagnosis, ~75% of patients are present with non-muscleinvasive bladder cancer (NMIBC), while the remaining 25% have muscleinvasive disease. High-risk recurrence and progression NMIBC cases are commonly treated with surgical resection of the tumor followed by weekly intravesical instillations of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) immunotherapy2. Despite its proven efﬁcacy, M. bovis BCG immunotherapy treatment fails in ~25– 45% of cases3. The efﬁcacy variationshave been related to many possible factors such as tumor development stage and heterogeneity, tumor microenvironment, genetic background, the immunological status of the patient, and intolerance to M. bovis BCGinstillations4, or even the patient microbiota, as recently suggested by observations in urine samples5,6. In addition, M. bovis BCG therapy is not | without risk: it can lead to local and, in rare cases, systemic infections. Therefore, alternative treatments are necessary. Mycobacterium brumae, anon-pathogenic environmental mycobacterium, achieves NMIBC antitumoral effects comparable to M. bovis BCG in vitro and in vivo without causing infections7–9, emerging as a safe immunotherapy agent.\u003Cbr>The long-standing notion of the urinary tract as a sterile environment has been overturned by the advent of high-throughput sequencing technologies, particularly 16S ribosomal RNA (16S rRNA) gene sequencing, which has enabled the identiﬁcation ofa resident urinary microbiota10. This revelation has sparked a revolution in urological research, reshaping our understanding of the ﬁeld11. The evidence of bladder microbiota may affect (bladder) tumor progression and response to therapies, including M. bovis BCG instillations, or may be potentially used as a noninvasive predictive response to treatment biomarkers12. Furthermore, urinary microbiota |  |\n\n1Genetics and Microbiology Department, Faculty of Biosciences, Autonomous University of Barcelona, Bellaterra Barcelona, Spain. 2Institute of Agrochemistry and Food Technology","cbCaiiLdmtanXMMf","https://ap.wps.com/l/cbCaiiLdmtanXMMf","pdf",3250611,13,"English","# Intravesical mycobacteria and clinical context\n## Bladder cancer burden and BCG therapy limitations\n## Urinary microbiota, sequencing, and predictive biomarkers\n# Study rationale and objectives\n## Unresolved bladder microbiota–BCG interaction\n## Proposed mechanisms\n## Need for standardized evidence\n# Experimental outcomes (microbiota changes across sites)","[{\"question\":\"What are the main factors driving interest in bladder microbiota for bladder cancer therapy?\",\"answer\":\"Bladder microbiota may affect tumor progression and responses to intravesical therapies, including BCG instillations, and could potentially serve as noninvasive predictive biomarkers for treatment outcomes.\"},{\"question\":\"Which mycobacterial treatments were compared in the study?\",\"answer\":\"The study evaluates the impact of Mycobacterium bovis BCG instillations and Mycobacterium brumae as a non-pathogenic immunomodulator on microbiota composition.\"},{\"question\":\"How did the treatments alter microbiota differently across body sites?\",\"answer\":\"Gut and bladder compartments showed distinct changes: mycobacterial instillations increased gut microbial richness but reduced Actinobacteria, while bladder communities displayed treatment-dependent shifts in dominant taxa and richness.\"}]","Intravesical mycobacteria reshape bladder and gut microbiota in a murine bladder cancer model | PDF",1790112439,33,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2796f0089a4b2b5dd732282df5f0ec47.webp",983,1305,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a3ebb270e484e104debb034bab35d07.webp",982,1304,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68871f1826620c3b7ed6773afb23cc30.webp",981,1303,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4be2affcccc85a6823b90068330060ab.webp",980,1301]